Introduction {#cam41333-sec-0001}
============

The use of histological subtype as a classification system for colorectal cancer was introduced by the World Health Organization in 1979. Carcinomas are categorized as traditional adenocarcinomas, mucinous adenocarcinomas (MA), signet‐ring cell carcinomas (SC), and other, more infrequent, types [1](#cam41333-bib-0001){ref-type="ref"}, [2](#cam41333-bib-0002){ref-type="ref"}. MA is a histological subtype of colon cancer in which the neoplastic cells secrete extensive extracellular mucins that form more than 50% of the tumor volume [3](#cam41333-bib-0003){ref-type="ref"}. SC tumors are comprised of more than 50% signet‐ring cells in which the nucleus is pushed to the periphery by intracytoplasmic mucins of colon cancer [4](#cam41333-bib-0004){ref-type="ref"}. This classification of histological subtype is routinely carried out during the postoperative pathological examination of colon cancer. However, how to this histological subtyping should best be used to aid in the clinical practice remains unclear.

In clinical practice, decision making regarding whether give or which regimen give adjuvant therapy to patients with stage II tumors remains controversial [5](#cam41333-bib-0005){ref-type="ref"}, [6](#cam41333-bib-0006){ref-type="ref"}. For patients with stage III disease, although the preferred treatment options are FOLFOX or CapeOx, the side effects of oxaliplatin are indisputable. It has been reported that oxaliplatin might not be applicable for all patients, specifically the elderly population [7](#cam41333-bib-0007){ref-type="ref"}, [8](#cam41333-bib-0008){ref-type="ref"}. Thus, it is important to find prognostic and predictive features to help assist with selecting appropriate and beneficial adjuvant therapy for patients considered. Histological subtype is not considered in the decision making for colon cancer adjuvant therapy in either the National Comprehensive Cancer Network (NCCN) [9](#cam41333-bib-0009){ref-type="ref"} or the European Society for Medical Oncology (ESMO) [10](#cam41333-bib-0010){ref-type="ref"}. In addition, no research has proposed that histological subtype could have an influence on chemotherapeutic effects in colorectal cancer patients. As for other types of cancer, Sugawa et al. [11](#cam41333-bib-0011){ref-type="ref"} found a difference in chemotherapy effects between different histological subtypes in cervical cancer, and Itaya et al. [12](#cam41333-bib-0012){ref-type="ref"} found histology‐dependent differences of chemosensitivity in nonsmall cell lung cancer.

The aim of this study was to compare the efficacy of postoperative chemotherapy among different histological subtypes of colon cancer. We then tried to find the most suitable postoperative chemotherapy regimens for both major histological subtypes of colonic adenocarcinoma.

Materials and Methods {#cam41333-sec-0002}
=====================

Data source {#cam41333-sec-0003}
-----------

This study was a retrospective analysis of data collected from the Surveillance, Epidemiology, and End Results (SEER)--Medicare linked database. This study was conducted in accordance with a SEER‐Medicare data use agreement, and a study protocol approval was also granted by the First Hospital of China Medical University Institutional Review Board.

SEER data contain information on patient demographics, tumor and disease characteristics, course of treatment, use of cancer‐directed operative and medical therapy, survival, and cause of death for individuals diagnosed with cancer. It is a population‐based cancer registry covering approximately 28% of the US population across several disparate geographic regions [13](#cam41333-bib-0013){ref-type="ref"}. Medicare is the primary health insurer for approximately 97% of the US population aged ≥65 years [14](#cam41333-bib-0014){ref-type="ref"}. The unmentioned details of the database appeared elsewhere [15](#cam41333-bib-0015){ref-type="ref"}.

Patient selection {#cam41333-sec-0004}
-----------------

All Medicare‐registered patients diagnosed with incident malignant primary colon cancer (SEER cancer site codes: 18.0, 18.2--18.9) between 1992 and 2008 in a SEER area were considered for study inclusion. The study contained two histological types defined by WHO International Classification of Diseases for Oncology, 3rd edition (ICD‐O‐3), codes: MA (8480) and nonmucinous adenocarcinomas (NMA) (8010, 8020--8022, 8140--8141, 8144--8145, 8210--8211, 8220--8221, 8230--8231, 8260--8263).

Patients were selected who underwent primary tumor resection with likely curative intent within 180 days of diagnosis. The No‐chemo group was designated as no claim of postoperative chemotherapy within 9 months after operation. The 5‐FU group consisted of patients who only received 5‐FU/capecitabine chemotherapy within 9 months of surgery. The oxaliplatin group comprised patients with any record of oxaliplatin plus 5‐FU/capecitabine within 9 months of surgery.

Patients were eliminated from the study population if they (1) received any preoperative adjuvant treatment; (2) received postoperative radiotherapy; (3) had prior noncolon cancer; (4) had incomplete histological subtype or pathological stage entries; (5) died within 30 days after tumor resection; (6) had stage I or stage IV tumors; (7) histological subtype was signet‐ring cell carcinoma, as this population represented too small a sample size (0.9%).

Variables {#cam41333-sec-0005}
---------

Subjects were categorized by age at diagnosis, year of diagnosis, gender, race, marital status, residence (rural or urban), median household income, level of education (percentage of people aged \>25 years with \<12 years of education), and the type of hospital in which they received care (teaching or nonteaching). To control for the effects of comorbidities, analyses were adjusted by the Centers for Medicare and Medicaid Services Hierarchical Condition Category (HCC) based on Medicare outpatient and inpatient claims for miscellaneous comorbidities within the 12 months before colon cancer diagnosis. The HCC risk score summarizes the healthcare problems and forecasts the future healthcare cost of a population compared with the average Medicare beneficiary [16](#cam41333-bib-0016){ref-type="ref"}.

Postoperative pathological stage was designated via the seventh edition of the Union for International Cancer Control (UICC) tumor‐node‐metastasis (TNM) staging system [17](#cam41333-bib-0017){ref-type="ref"}. Other covariates included histological grade, histological subtype, intestinal obstruction, intestinal perforation, and the number of lymph nodes examined.

Statistical analysis {#cam41333-sec-0006}
--------------------

The chi‐square test was used to compare demographics and tumor characteristics between the different groups. In the univariate survival analysis, cancer‐specific survival (CSS) was analyzed by the Kaplan--Meier method. Comparison of survival curves was carried out using the log‐rank test. Because treatment choice estimates are likely confounded by factors related to treatment selection, a propensity score (PS)‐matched analysis was performed to compare the effect of treatment on survival among patients of similar risk profiles as assessed by measured known confounders [18](#cam41333-bib-0018){ref-type="ref"}, [19](#cam41333-bib-0019){ref-type="ref"}. Propensity score matching is a statistical procedure for reducing this bias by assembling a sample in which confounding factors are balanced between treatment groups. Univariate logistic regression was used to find factors related to treatment selection (*P *\<* *0.05). Multivariate logistic regression was used to estimate the propensity scores in each group (Table [1](#cam41333-tbl-0001){ref-type="table-wrap"}). The propensity score‐matched sample would then be constructed using "psmatch2" software package in STATA 14.0. A Cox proportional hazards model was also used in the adjusted analysis. The covariates included all variables that were identified to be significantly related to survival in the univariate analysis.

###### 

Main effect variables in propensity score models

  ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NMA Patients in low‐risk stage II                                                                                               
  Variables that significantly related to the patients' probability of receiving 5‐FU compared with No‐chemo                      Gender, age at diagnosis, year at diagnosis, HCC risk score, race, marital status
  MA Patients in low‐risk stage II                                                                                                
  Variables that significantly related to the patients' probability of receiving 5‐FU compared with No‐chemo                      Gender, age at diagnosis, year at diagnosis
  NMA Patients in high‐risk stage II                                                                                              
  Variables that significantly related to the patients' probability of receiving 5‐FU compared with No‐chemo                      Gender, age at diagnosis, year at diagnosis, histological grade, pT category, intestinal obstruction, HCC risk score, number of examined lymph node, level of education, marital status, residence location
  Variables that significantly related to the patients' probability of receiving 5‐FU plus oxaliplatin compared with 5‐FU alone   Age at diagnosis, year at diagnosis, pT category, number of examined lymph node, median income, marital status
  MA Patients in high‐risk stage II                                                                                               
  Variables that significantly related to the patients' probability of receiving 5‐FU compared with No‐chemo                      Gender, age at diagnosis, year at diagnosis, pT category, intestinal obstruction, HCC risk score, marital status, profit hospital
  Variables that significantly related to the patients' probability of receiving 5‐FU plus oxaliplatin compared with 5‐FU alone   Year at diagnosis, pT category, number of examined lymph node, profit hospital
  NMA Patients in stage III                                                                                                       
  Variables that significantly related to the patients' probability of receiving 5‐FU compared with No‐chemo                      Gender, age at diagnosis, year at diagnosis, pT category, pN category, intestinal obstruction, HCC risk score, level of education, median income, race, marital status, residence location
  Variables that significantly related to the patients' probability of receiving 5‐FU plus oxaliplatin compared with 5‐FU alone   Age at diagnosis, year at diagnosis, pN category, number of examined lymph node, level of education, median income, marital status
  MA Patients in stage III                                                                                                        
  Variables that significantly related to the patients' probability of receiving 5‐FU compared with No‐chemo                      Gender, age at diagnosis, year at diagnosis, pT category, intestinal obstruction, HCC risk score, marital status
  Variables that significantly related to the patients' probability of receiving 5‐FU plus oxaliplatin compared with 5‐FU alone   Gender, age at diagnosis, year at diagnosis, pN category, number of examined lymph node, median income, marital status
  ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MA, mucinous adenocarcinoma; NMA, nonmucinous adenocarcinoma; HCC, hierarchical condition categories; 5‐FU, 5‐fluorouracil.
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All statistical analyses and graphics were performed using SAS 9.4 (SAS Institute, Cary, NC), STATA 14.0 software (STATA, College Station, TX), and PASW Statistics 20.0 software (SPSS, Inc., Somers, NY). For all analyses, a *P* value \< 0.05 was considered statistically significant.

Results {#cam41333-sec-0007}
=======

Patient characteristics {#cam41333-sec-0008}
-----------------------

Selected 51,200 individuals were stratified into two analysis groups: NMA (*n* = 43,998) and MA (*n* = 7202). Demographic characteristics of patients are depicted in Table [2](#cam41333-tbl-0002){ref-type="table-wrap"}. Compared with NMA, MA was more common in women (*P *\<* *0.001), individuals aged \>80 years (*P *=* *0.018), year at diagnosis before 2004 (*P *\<* *0.001), well histological grade (*P *\<* *0.001), T1--T3 category (*P *\<* *0.001), N2 category (*P *\<* *0.001), nonintestinal obstruction (*P *\<* *0.001), number of examined lymph nodes ≥12 (*P *\<* *0.001), white race (*P *\<* *0.001), widowed (*P *=* *0.006). Stage II patients were further divided into low‐risk stage II and high‐risk stage II groups. We designated the cohort of patients with high‐risk stage II using features of poor prognosis referred to in the NCCN [9](#cam41333-bib-0009){ref-type="ref"}, including T4 tumors, poorly differentiated histology, bowel obstruction, bowel perforation, and inadequate sampled nodes (\<12 lymph nodes). The number of patients and the results of each analysis and treatment chemotherapy effect analysis are summarized in Table [3](#cam41333-tbl-0003){ref-type="table-wrap"}.

###### 

Clinicopathologic features of patients with different histological subtype

                                                              NMA              MA
  ----------------------------------------------------------- ---------------- --------------
  Gender                                                      \<0.001          
  Male                                                        18,479 (42.0%)   2665 (37.0%)
  Female                                                      25,519 (58.0%)   4537 (63.0%)
  Age at diagnosis, years                                     0.018            
  \<70                                                        6712 (15.3%)     1027 (14.3%)
  70--74                                                      8840 (20.1%)     1411 (19.6%)
  75--79                                                      10,066 (22.9%)   1610 (22.4%)
  80--84                                                      9205 (20.9%)     1563 (21.7%)
  \>84                                                        9175 (20.9%)     1591 (22.1%)
  Year at diagnosis                                           0.001            
  1992--1996                                                  8818 (20.0%)     1472 (20.4%)
  1997--2000                                                  8393 (19.1%)     1421 (19.7%)
  2001--2004                                                  14,410 (32.8%)   2452 (34.0%)
  2005--2008                                                  12,377 (28.1%)   1857 (25.8%)
  Histological grade                                          \<0.001          
  Well                                                        2695 (6.1%)      658 (9.1%)
  Moderate                                                    30,354 (69.0%)   4470 (62.1%)
  Poor                                                        9707 (22.1%)     1475 (20.5%)
  Undifferentiated                                            503 (1.1%)       77 (1.1%)
  Unknown                                                     739 (1.7%)       522 (7.2%)
  Postoperative chemotherapy                                  0.396            
  No                                                          28,104 (63.9%)   4563 (63.4%)
  Yes                                                         15,894 (36.1%)   2639 (36.6%)
  pT category                                                 \<0.001          
  T1                                                          612 (1.4%)       57 (0.8%)
  T2                                                          1504 (3.4%)      197 (2.7%)
  T3                                                          35,209 (80.0%)   5661 (78.6%)
  T4a                                                         4134 (9.4%)      787 (10.9%)
  T4b                                                         2539 (5.8%)      500 (6.9%)
  pN category                                                 \<0.001          
  N0                                                          24,869 (56.5%)   4105 (57.0%)
  N1a                                                         6852 (15.6%)     1016 (14.1%)
  N1b                                                         6422 (14.6%)     992 (13.8%)
  N2a                                                         3652 (8.3%)      604 (8.4%)
  N2b                                                         2203 (5.0%)      485 (6.7%)
  Intestinal obstruction                                      \<0.001          
  No                                                          34,677 (78.8%)   5910 (82.1%)
  Yes                                                         9321 (21.2%)     1292 (17.9%)
  Intestinal perforation                                      0.463            
  No                                                          43,401 (98.6%)   7112 (98.8%)
  Yes                                                         597 (1.4%)       90 (1.2%)
  HCC risk score                                              0.001            
  1st quartile                                                11,575 (26.3%)   1974 (27.4%)
  2nd quartile                                                10,846 (24.7%)   1707 (23.7%)
  3rd quartile                                                10,892 (24.8%)   1671 (23.2%)
  4th quartile                                                10,685 (24.3%)   1850 (25.7%)
  Number of examined lymph node                               \<0.001          
  \<12                                                        20,747 (47.2%)   3164 (43.9%)
  ≥12                                                         23,251 (52.8%)   4038 (56.1%)
  Level of education                                          0.712            
  1st quartile                                                11,129 (25.3%)   1845 (25.6%)
  2nd quartile                                                11,088 (25.2%)   1828 (25.4%)
  3rd quartile                                                10,974 (24.9%)   1772 (24.6%)
  4th quartile                                                8899 (20.2%)     1426 (19.8%)
  Unknown                                                     1908 (4.3%)      331 (4.6%)
  Median income                                               0.061            
  1st quartile                                                10,858 (24.7%)   1815 (25.2%)
  2nd quartile                                                11,072 (25.2%)   1698 (23.6%)
  3rd quartile                                                11,063 (25.1%)   1828 (25.4%)
  4th quartile                                                9097 (20.7%)     1530 (21.2%)
  Unknown                                                     1908 (4.3%)      331 (4.6%)
  Race                                                        \<0.001          
  White                                                       37,285 (84.7%)   6279 (87.2%)
  Black                                                       3859 (8.8%)      560 (7.8%)
  Asian                                                       1303 (3.0%)      149 (2.1%)
  Others                                                      1551 (3.5%)      214 (3.0%)
  Marital status                                              0.006            
  Single                                                      4042 (9.2%)      636 (8.8%)
  Married                                                     20,997 (47.7%)   3341 (46.4%)
  Widowed                                                     17,487 (39.7%)   3011 (41.8%)
  Others                                                      1472 (3.3%)      214 (3.0%)
  Residence location[a](#cam41333-note-0005){ref-type="fn"}   0.127            
  Big Metro                                                   23,585 (53.6%)   3938 (54.7%)
  Metro or Urban                                              15,298 (34.8%)   2416 (33.5%)
  Less Urban or Rural                                         5113 (11.6%)     848 (11.8%)
  Profit hospital[a](#cam41333-note-0005){ref-type="fn"}      0.006            
  Nonprofit hospital                                          21,362 (49.4%)   3620 (51.1%)
  For‐profit hospital                                         15,938 (36.9%)   2586 (36.5%)
  Public hospital                                             5924 (13.7%)     885 (12.5%)
  Number of beds[a](#cam41333-note-0005){ref-type="fn"}       0.076            
  1st quartile                                                10,653 (24.6%)   1772 (25.0%)
  2nd quartile                                                10,795 (25.0%)   1823 (25.7%)
  3rd quartile                                                10,819 (25.0%)   1800 (25.4%)
  4th quartile                                                10,957 (25.3%)   1696 (23.9%)
  Teaching hospital[a](#cam41333-note-0005){ref-type="fn"}    0.941            
  Yes                                                         22,604 (52.7%)   3699 (52.6%)
  No                                                          20,304 (47.3%)   3329 (47.4%)

HCC, hierarchical condition categories; NMA, nonmucinous adenocarcinomas; MA, mucinous adenocarcinomas.

Variables have missing data.
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###### 

Results of patients subjected to different chemotherapy regimens

                                      Number of patients   HR     95% CI   *P*                     
  ----------------------------------- -------------------- ------ -------- ------- --------------- ---------
  Low‐risk stage II                                                                                
  No‐PSM‐NMA (No‐ chemo vs. 5‐FU)     5958                 961    --       0.735   0.604--0.893    0.002
  No‐PSM‐NMA (5‐FU vs. oxaliplatin)   --                   961    94       0.462   0.146--1.465    0.179
  No‐PSM‐MA (No‐ chemo vs. 5‐FU)      1025                 178    --       0.934   0.582--1.496    0.775
  No‐PSM‐MA (5‐FU vs. oxaliplatin)    --                   178    13       0.045   0.001--843.46   0.346
  PSM‐NMA (No‐chemo vs. 5‐FU)         961                  961    --       0.939   0.726--1.214    0.629
  PSM‐MA (No‐chemo vs. 5‐FU)          176                  176    --       1.399   0.690--2.598    0.387
  High‐risk stage II                                                                               
  No‐PSM‐NMA (No‐chemo vs. 5‐FU)      13,951               2664   --       0.826   0.758--0.901    \<0.001
  No‐PSM‐NMA (5‐FU vs. oxaliplatin)   --                   2664   260      0.529   0.348--0.804    0.002
  No‐PSM‐MA (No‐chemo vs. 5‐FU)       2028                 443    --       0.749   0.598--0.938    0.011
  No‐PSM‐MA (5‐FU vs. oxaliplatin)    --                   443    37       0.792   0.289--2.172    0.649
  PSM‐NMA (No‐chemo vs. 5‐FU)         2662                 2662   --       1.003   0.894--1.125    0.961
  PSM‐NMA (5‐FU vs. oxaliplatin)      --                   260    260      0.529   0.348--0.804    0.004
  PSM‐MA (No‐chemo vs. 5‐FU)          436                  436    --       1.049   0.778--1.415    0.754
  PSM‐MA (5‐FU vs. oxaliplatin)       --                   29     29       0.792   0.289--2.172    0.690
  Stage III                                                                                        
  No‐PSM‐NMA (No‐chemo vs. 5‐FU)      7843                 8188   --       0.551   0.525--0.578    \<0.001
  No‐PSM‐NMA (5‐FU vs. oxaliplatin)   --                   8188   1826     0.583   0.522--0.625    \<0.001
  No‐PSM‐MA (No‐chemo vs. 5‐FU)       1287                 1360   --       0.566   0.503--0.637    \<0.001
  No‐PSM‐MA (5‐FU vs. oxaliplatin)    --                   1360   258      0.74    0.569--0.962    0.023
  PSM‐NMA (No‐chemo vs. 5‐FU)         7841                 7841   --       0.554   0.527--0.581    \<0.001
  PSM‐NMA (5‐FU vs. oxaliplatin)      --                   1819   1819     0.621   0.543--0.710    \<0.001
  PSM‐MA (No‐chemo vs. 5‐FU)          1287                 1287   --       0.567   0.502--0.639    \<0.001
  PSM‐MA (5‐FU vs. oxaliplatin)       --                   252    252      0.837   0.598--1.173    0.300

PSM, propensity score matched; MA, mucinous adenocarcinoma; NMA, nonmucinous adenocarcinoma; HR, hazard ratio; CI, confidential intervals; 5‐FU, 5‐fluorouracil; No‐chemo, without postoperative chemotherapy.
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CSS in low‐risk stage II adenocarcinoma {#cam41333-sec-0009}
---------------------------------------

There was a significant difference in survival for NMA patients with low‐risk stage II cancer between the no‐chemo and 5‐FU groups (*P *=* *0.002, Fig. [1](#cam41333-fig-0001){ref-type="fig"}A), while those with MA saw no difference (*P *=* *0.775, Fig. [1](#cam41333-fig-0001){ref-type="fig"}B). There was no significant difference in NMA and MA patients with low‐risk stage II cancer between the 5‐FU and oxaliplatin groups (Fig. [1](#cam41333-fig-0001){ref-type="fig"}C and D).

![Kaplan--Meier comparison of cancer‐specific survival among patients who received different postoperative treatment stratified by histological subtype. (A) NMA in low‐risk stage II (No‐chemo vs. 5‐FU); (B) MA in low‐risk stage II (No‐chemo vs. 5‐FU); (C) NMA in low‐risk stage II (5‐FU vs. oxaliplatin); (D) MA in low‐risk stage II (5‐FU vs. oxaliplatin); (E) NMA in low‐risk stage II after PS‐matched (No‐chemo vs. 5‐FU); (F) MA in low‐risk stage II after PS‐matched (No‐chemo vs. 5‐FU).](CAM4-7-600-g001){#cam41333-fig-0001}

A PS‐matched cohort was generated using related variables which may interfere with the chemotherapy decision (Table [1](#cam41333-tbl-0001){ref-type="table-wrap"}). The aforementioned general results were recalculated in the PS‐match cohorts. There was no significant difference in survival for patients with low‐risk stage II NMA between the no‐chemo and 5‐FU groups (*P *=* *0.629, Fig. [1](#cam41333-fig-0001){ref-type="fig"}E), while those with MA again saw no difference (*P *=* *0.387, Fig. [1](#cam41333-fig-0001){ref-type="fig"}F). Another PS‐matched cohort was generated using related variables which may interfere with the choice of chemotherapy regimen. However, its sample size is too small to recalculate aforementioned results.

CSS in high‐risk stage II adenocarcinoma {#cam41333-sec-0010}
----------------------------------------

There was a significant difference in survival for patients with high‐risk stage II NMA between the no‐chemo and 5‐FU groups (*P *\<* *0.001, Fig. [2](#cam41333-fig-0002){ref-type="fig"}A), while those with MA again saw a difference (*P *=* *0.011, Fig. [2](#cam41333-fig-0002){ref-type="fig"}B). Patients with NMA who received the oxaliplatin chemotherapy regimen had significantly improved CSS (*P *=* *0.002, Fig. [2](#cam41333-fig-0002){ref-type="fig"}C) compared with the 5‐FU group, while those with MA saw no improvement (*P *=* *0.649, Fig. [2](#cam41333-fig-0002){ref-type="fig"}D).

![Kaplan--Meier comparison of cancer‐specific survival among patients who received different postoperative treatment stratified by histological subtype. (A) NMA in high‐risk stage II (No‐chemo vs. 5‐FU); (B) MA in high‐risk stage II (No‐chemo vs. 5‐FU); (C) NMA in high‐risk stage II (5‐FU vs. oxaliplatin); (D) MA in high‐risk stage II (5‐FU vs. oxaliplatin).](CAM4-7-600-g002){#cam41333-fig-0002}

Then, we used the PS‐match cohorts to recalculate the aforementioned general results. There was no significant difference in survival for patients with high‐risk stage II NMA between the no‐chemo and 5‐FU groups (*P *=* *0.961, Fig. [3](#cam41333-fig-0003){ref-type="fig"}A), while those with MA again saw no difference (*P *=* *0.754, Fig. [3](#cam41333-fig-0003){ref-type="fig"}B). Patients with NMA who received the oxaliplatin chemotherapy regimen had significantly improved CSS (*P *=* *0.004, Fig. [3](#cam41333-fig-0003){ref-type="fig"}C) compared with the 5‐FU group, while those with MA saw no improvement (*P *=* *0.690, Fig. [3](#cam41333-fig-0003){ref-type="fig"}D). This result was also verified by a Cox proportional hazards model (Table [4](#cam41333-tbl-0004){ref-type="table-wrap"} and [5](#cam41333-tbl-0005){ref-type="table-wrap"}).

![After PS‐matched, Kaplan--Meier comparison of cancer‐specific survival among patients who received different postoperative treatment stratified by histological subtype. (A) NMA in high‐risk stage II (No‐chemo vs. 5‐FU); (B) MA in high‐risk stage II (No‐chemo vs. 5‐FU); (C) NMA in high‐risk stage II (5‐FU vs. oxaliplatin); (D) MA in high‐risk stage II (5‐FU vs. oxaliplatin).](CAM4-7-600-g003){#cam41333-fig-0003}

###### 

Cox proportional hazards model for patients in high‐risk stage II stratified by histological subtype

                                  HR      95% CI         *P*
  ------------------------------- ------- -------------- ---------
  NMA                                                    
  Chemotherapy regimen                                   
  5‐FU                            1                      
  Oxaliplatin                     0.867   0.564--0.366   0.009
  Intestinal perforation                                 
  No                              1                      
  Yes                             2.165   1.449‐0.970    0.070
  Intestinal obstruction                                 
  No                              1                      
  Yes                             1.619   1.356--1.135   0.001
  Number of examined lymph node                          
  \<12                            1                      
  ≥12                             0.817   0.681--0.568   \<0.001
  HCC risk score                                         
  1st quartile                    1                      
  2nd quartile                    1.584   1.227--0.950   0.118
  3rd quartile                    1.679   1.303--1.010   0.041
  4th quartile                    1.692   1.289--0.982   0.068
  Race                                                   
  White                           1                      
  Black                           2.025   1.504--1.116   0.007
  Asian                           0.863   0.472--0.258   0.015
  Others                          1.167   0.715--0.438   0.179
  pT category                                            
  T3                              1                      
  T4a                             1.739   1.383--1.100   0.005
  T4b                             3.419   2.763--2.233   \<0.001
  Age at diagnosis, years                                
  \<70                            1                      
  70--74                          1.653   1.311--1.039   0.022
  75--79                          1.947   1.543--1.222   \<0.001
  80--84                          2.533   1.917--1.450   \<0.001
  \>84                            5.814   3.870--2.577   \<0.001
  Marital status                                         
  Single                          1                      
  Married                         1.028   0.780--0.591   0.078
  Widowed                         1.343   1.005--0.752   0.973
  Others                          1.460   0.851--0.496   0.557
  Level of education                                     
  1st quartile                    1                      
  2nd quartile                    1.259   1.002--0.798   0.984
  3rd quartile                    1.134   0.903--0.719   0.380
  4th quartile                    1.266   0.995--0.782   0.969
  Gender                                                 
  Male                            1                      
  Female                          1.133   0.938--0.777   0.507
  MA                                                     
  Chemotherapy regimen                                   
  5‐FU                            1                      
  Oxaliplatin                     0.622   0.224--1.732   0.364
  Intestinal perforation                                 
  No                              1                      
  Yes                             1.827   0.712--4.683   0.210
  Intestinal obstruction                                 
  No                              1                      
  Yes                             1.050   0.634--1.738   0.851
  pT category                                            
  T3                              1                      
  T4a                             1.543   0.910--2.616   0.108
  T4b                             3.666   2.244--5.990   \<0.001
  Age at diagnosis, years                                
  \<70                            1                      
  70--74                          0.870   0.500--1.513   0.622
  75--79                          0.985   0.550--1.762   0.959
  80--84                          1.816   0.912--3.615   0.090
  \>84                            2.731   1.204--6.199   0.016
  Marital status                                         
  Single                          1                      
  Married                         0.563   0.292--1.088   0.087
  Widowed                         0.517   0.253--1.060   0.072
  Others                          0.227   0.028--1.837   0.165

MA, mucinous adenocarcinoma; NMA, nonmucinous adenocarcinoma; HCC, hierarchical condition categories; HR, hazard ratio; CI, confidential intervals; 5‐FU, 5‐fluorouracil.
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###### 

Univariate prognostic analysis stratified by histological subtype

                                  HR      95% CI          *P*
  ------------------------------- ------- --------------- ---------
  NMA in stage III                                        
  Age at diagnosis, years                                 
  \<70                            1                       
  70--74                          1.070   0.991--1.155    0.082
  75--79                          1.217   1.130--1.311    \<0.001
  80--84                          1.468   1.361--1.583    \<0.001
  \>84                            2.021   1.875--2.179    \<0.001
  Year at diagnosis                                       
  1992--1996                      1                       
  1997--2000                      1.000   0.934--1.070    0.989
  2001--2004                      0.925   0.870--0.984    0.014
  2005--2008                      0.850   0.794--0.910    \<0.001
  HCC risk score                                          
  1st quartile                    1                       
  2nd quartile                    0.838   0.787--0.891    \<0.001
  3rd quartile                    0.905   0.850--0.964    0.002
  4th quartile                    1.117   1.050--1.189    \<0.001
  Number of examined lymph node                           
  \<12                            1                       
  ≥12                             0.890   0.851--0.930    \<0.001
  pT category                                             
  T1                              1                       
  T2                              1.240   0.994--1.547    0.057
  T3                              2.804   2.311--3.401    \<0.001
  T4a                             4.124   3.375--5.039    \<0.001
  T4b                             7.451   6.087--9.120    \<0.001
  Intestinal perforation                                  
  No                              1                       
  Yes                             2.259   1.928--2.648    \<0.001
  Intestinal obstruction                                  
  No                              1                       
  Yes                             1.549   1.473--1.629    \<0.001
  Marital status                                          
  Single                          1                       
  Married                         0.793   0.733--0.858    \<0.001
  Widowed                         1.007   0.930--1.091    0.864
  Others                          0.926   0.802--1.070    0.299
  Chemotherapy regimen                                    
  5‐FU                            1                       
  Oxaliplatin                     0.583   0.522--0.652    \<0.001
  Histological grade                                      
  Well                            1                       
  Moderate                        1.264   1.123--1.422    \<0.001
  Poor                            1.801   1.595--2.034    \<0.001
  Undifferentiated                1.902   1.550--2.334    \<0.001
  Unknown                         1.223   0.993--1.507    0.059
  Median income                                           
  1st quartile                    1                       
  2nd quartile                    0.938   0.881--0.997    0.041
  3rd quartile                    0.905   0.850--0.963    0.002
  4th quartile                    0.858   0.803--0.918    \<0.001
  Unknown                         1.027   0.919--1.148    0.639
  pN category                                             
  N1a                             1                       
  N1b                             1.417   1.337--1.503    \<0.001
  N2a                             2.000   1.877--2.131    \<0.001
  N2b                             3.272   3.056--3.503    \<0.001
  Race                                                    
  White                           1                       
  Black                           1.066   0.988--1.149    0.098
  Asian                           0.750   0.653--0.86     \<0.001
  Others                          0.945   0.843--1.06     0.338
  Level of education                                      
  1st quartile                    1                       
  2nd quartile                    1.091   1.024--1.163    0.007
  3rd quartile                    1.140   1.069--1.215    \<0.001
  4th quartile                    1.195   1.118--1.278    \<0.001
  Unknown                         1.219   1.090--1.364    0.001
  Gender                                                  
  Male                            1                       
  Female                          1.069   1.022--1.119    0.004
  MA in stage III                                         
  Age at diagnosis, years                                 
  \<70                            1                       
  70--74                          1.037   0.857--1.256    0.706
  75--79                          1.216   1.011--1.464    0.038
  80--84                          1.405   1.164--1.696    \<0.001
  \>84                            1.692   1.401--2.045    \<0.001
  Year at diagnosis                                       
  1992--1996                      1                       
  1997--2000                      1.040   0.881--1.227    0.643
  2001--2004                      1.032   0.889--1.198    0.677
  2005--2008                      0.826   0.694--0.983    0.032
  HCC risk score                                          
  1st quartile                    1                       
  2nd quartile                    0.847   0.724--0.991    0.038
  3rd quartile                    0.986   0.844--1.151    0.854
  4th quartile                    1.203   1.037--1.396    0.015
  Number of examined lymph node                           
  \<12                            1                       
  ≥12                             0.792   0.710--0.884    \<0.001
  pT category                                             
  T1                              1                       
  T2                              0.841   0.445--1.590    0.595
  T3                              2.214   1.280--3.828    0.004
  T4a                             3.590   2.048--6.295    \<0.001
  T4b                             5.753   3.270--10.122   \<0.001
  Intestinal obstruction                                  
  No                              1                       
  Yes                             1.634   1.436--1.859    \<0.001
  Marital status                                          
  Single                          1                       
  Married                         0.776   0.636--0.948    0.013
  Widowed                         0.941   0.770--1.151    0.555
  Others                          1.089   0.780--1.520    0.618
  pN category                                             
  N1a                             1                       
  N1b                             1.208   1.040--1.402    0.013
  N2a                             1.905   1.628--2.228    \<0.001
  N2b                             2.752   2.344--3.231    \<0.001
  Intestinal perforation                                  
  No                              1                       
  Yes                             1.915   1.151--3.188    0.012
  Chemotherapy regimen                                    
  5‐FU                            1                       
  Oxaliplatin                     0.740   0.569--0.962    0.025
  Histological grade                                      
  Well                            1                       
  Moderate                        0.955   0.763--1.197    0.692
  Poor                            1.332   1.053--1.685    0.017
  Undifferentiated                1.701   1.073--2.697    0.024
  Unknown                         1.129   0.847--1.503    0.407
  NMA in high‐risk stage II                               
  Intestinal perforation                                  
  No                              1                       
  Yes                             2.666   2.249--3.161    \<0.001
  Chemotherapy regimen                                    
  5‐FU                            1                       
  Oxaliplatin                     0.529   0.348--0.804    0.003
  Intestinal obstruction                                  
  No                              1                       
  Yes                             1.510   1.413--1.613    \<0.001
  Number of examined lymph node                           
  \<12                            1                       
  ≥12                             0.921   0.859--0.987    0.020
  HCC risk score                                          
  1st quartile                    1                       
  2nd quartile                    0.925   0.847--1.011    0.087
  3rd quartile                    1.045   0.958--1.141    0.321
  4th quartile                    1.286   1.178--1.404    \<0.001
  Race                                                    
  White                           1                       
  Black                           1.424   1.284--1.580    \<0.001
  Asian                           0.698   0.560--0.870    0.001
  Others                          1.033   0.863--1.235    0.726
  pT category                                             
  T3                              1                       
  T4a                             1.357   1.238--1.489    \<0.001
  T4b                             2.589   2.348--2.855    \<0.001
  Age at diagnosis, years                                 
  \<70                            1                       
  70--74                          0.969   0.858--1.094    0.612
  75--79                          1.210   1.079--1.358    0.001
  80--84                          1.416   1.262--1.588    \<0.001
  \>84                            2.026   1.813--2.265    \<0.001
  Marital status                                          
  Single                          1                       
  Married                         0.652   0.586--0.727    \<0.001
  Widowed                         0.881   0.792--0.980    0.020
  Others                          0.693   0.562--0.854    0.001
  Level of education                                      
  1st quartile                    1                       
  2nd quartile                    1.038   0.946--1.139    0.432
  3rd quartile                    1.107   1.012--1.211    0.027
  4th quartile                    1.218   1.108--1.338    \<0.001
  Unknown                         1.148   0.971--1.356    0.106
  Gender                                                  
  Male                            1                       
  Female                          0.935   0.877--0.996    0.038
  MA in high‐risk stage II                                
  Chemotherapy regimen                                    
  5‐FU                            1                       
  Oxaliplatin                     0.792   0.289--2.172    0.650
  Intestinal perforation                                  
  No                              1                       
  Yes                             2.439   1.577--3.773    \<0.001
  Intestinal obstruction                                  
  No                              1                       
  Yes                             1.500   1.252--1.796    \<0.001
  pT category                                             
  T3                              1                       
  T4a                             1.585   1.276--1.968    \<0.001
  T4b                             2.610   2.055--3.314    \<0.001
  Age at diagnosis, years                                 
  \<70                            1                       
  70--74                          1.061   0.773--1.456    0.713
  75--79                          1.102   0.808--1.504    0.538
  80--84                          1.198   0.882--1.628    0.248
  \>84                            2.013   1.507--2.690    \<0.001
  Marital status                                          
  Single                          1                       
  Married                         0.638   0.480--0.847    0.002
  Widowed                         0.876   0.663--1.158    0.351
  Others                          0.716   0.393--1.303    0.274

MA, mucinous adenocarcinomas; NMA, nonmucinous adenocarcinomas; HCC, hierarchical condition categories; 5‐FU, 5‐fluorouracil; HR, hazard ratio; CI, confidential intervals.
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An interaction analysis was performed between chemotherapy regimen (5‐FU or oxaliplatin) and histological type for patients with high‐risk stage II adenocarcinoma. No significant interaction effects were found in the test (*P *=* *0.750).

CSS in stage III adenocarcinoma {#cam41333-sec-0011}
-------------------------------

The prognosis for patients with stage III NMA in the no‐chemo group was significantly worse than the 5‐FU group (*P *\<* *0.001, Fig. [4](#cam41333-fig-0004){ref-type="fig"}A). Similar results were also found for MA patients (*P *\<* *0.001, Fig. [4](#cam41333-fig-0004){ref-type="fig"}B). Patients with NMA who received the oxaliplatin chemotherapy regimen had significantly improved CSS (*P *\<* *0.001, Fig. [4](#cam41333-fig-0004){ref-type="fig"}C) compared with the 5‐FU group. Likewise, we found a survival benefit for patients with stage III MA receiving oxaliplatin compared to the 5‐FU group (*P *=* *0.023, Fig. [4](#cam41333-fig-0004){ref-type="fig"}D).

![Kaplan--Meier comparison of cancer‐specific survival among patients who received different postoperative treatment stratified by histological subtype. (A) NMA in stage III (No‐chemo vs. 5‐FU); (B) MA in stage III (No‐chemo vs. 5‐FU); (C) NMA in stage III (5‐FU vs. oxaliplatin); (D) MA in stage III (5‐FU vs. oxaliplatin).](CAM4-7-600-g004){#cam41333-fig-0004}

The aforementioned results were recalculated in the PS‐matched cohorts. The prognosis of patients with stage III NMA in the no‐chemo group was significantly worse than in the 5‐FU group (*P *\<* *0.001, Fig. [5](#cam41333-fig-0005){ref-type="fig"}A). Similar results were also seen for MA patients (*P *\<* *0.001, Fig. [5](#cam41333-fig-0005){ref-type="fig"}B). Patients with NMA who received the oxaliplatin chemotherapy regimen had significantly improved CSS (*P *\<* *0.001, Fig. [5](#cam41333-fig-0005){ref-type="fig"}C) compared with the 5‐FU group. However, we did not find a similar survival benefit for patients with stage III MA between the oxaliplatin and 5‐FU groups (*P *=* *0.300, Fig. [5](#cam41333-fig-0005){ref-type="fig"}D). This result was also verified by a Cox proportional hazards model (Table [5](#cam41333-tbl-0005){ref-type="table-wrap"} and [6](#cam41333-tbl-0006){ref-type="table-wrap"}). The result of the interaction analysis showed that there was a significant interaction effect seen in the test (*P *=* *0.040).

![After PS‐matched, Kaplan--Meier comparison of cancer‐specific survival among patients who received different postoperative treatment stratified by histological subtype. (A) NMA in stage III (No‐chemo vs. 5‐FU); (B) MA in stage III (No‐chemo vs. 5‐FU); (C) NMA in stage III (5‐FU vs. oxaliplatin); (D) MA in stage III (5‐FU vs. oxaliplatin).](CAM4-7-600-g005){#cam41333-fig-0005}

###### 

Cox proportional hazards model for patients in stage III stratified by histological subtype

                                  HR      95% CI         *P*
  ------------------------------- ------- -------------- ---------
  NMA                                                    
  Chemotherapy regimen                                   
  5‐FU                            1                      
  Oxaliplatin                     0.601   0.525--0.687   \<0.001
  Age at diagnosis, years                                
  \<70                            1                      
  70--74                          0.986   0.896--1.086   0.781
  75--79                          1.013   0.917--1.119   0.795
  80--84                          1.294   1.158--1.445   \<0.001
  \>84                            1.627   1.393--1.901   \<0.001
  Year at diagnosis                                      
  1992--1996                      1                      
  1997--2000                      0.905   0.822--0.997   0.044
  2001--2004                      0.766   0.698--0.840   \<0.001
  2005--2008                      0.794   0.698--0.903   \<0.001
  HCC risk score                                         
  1st quartile                    1                      
  2nd quartile                    1.048   0.944--1.163   0.381
  3rd quartile                    1.111   0.999--1.234   0.051
  4th quartile                    1.245   1.116--1.388   \<0.001
  Number of examined lymph node                          
  \<12                            1                      
  ≥12                             0.791   0.738--0.848   \<0.001
  pT category                                            
  T1                              1                      
  T2                              0.965   0.718--1.298   0.815
  T3                              1.961   1.523--2.525   \<0.001
  T4a                             2.691   2.062--3.510   \<0.001
  T4b                             4.094   3.112--5.385   \<0.001
  Intestinal perforation                                 
  No                              1                      
  Yes                             1.856   1.391--2.477   \<0.001
  Intestinal obstruction                                 
  No                              1                      
  Yes                             1.307   1.207--1.415   \<0.001
  Marital status                                         
  Single                          1                      
  Married                         0.884   0.782--1.000   0.049
  Widowed                         0.980   0.862--1.114   0.754
  Others                          0.949   0.759--1.185   0.642
  Histological grade                                     
  Well                            1                      
  Moderate                        1.160   0.975--1.381   0.094
  Poor                            1.461   1.221--1.749   \<0.001
  Undifferentiated                1.575   1.143--2.172   0.006
  Unknown                         1.209   0.887--1.649   0.231
  Median income                                          
  1st quartile                    1                      
  2nd quartile                    1.085   0.982--1.199   0.107
  3rd quartile                    1.150   1.028--1.286   0.014
  4th quartile                    1.155   1.006--1.326   0.041
  pN category                                            
  N1a                             1                      
  N1b                             1.360   1.244--1.486   \<0.001
  N2a                             1.962   1.783--2.159   \<0.001
  N2b                             3.624   3.259--4.029   \<0.001
  Race                                                   
  White                           1                      
  Black                           1.076   0.952--1.215   0.240
  Asian                           0.806   0.664--0.977   0.028
  Others                          0.975   0.821--1.157   0.771
  Level of education                                     
  1st quartile                    1                      
  2nd quartile                    1.041   0.939--1.154   0.445
  3rd quartile                    1.148   1.025--1.286   0.017
  4th quartile                    1.270   1.111--1.452   \<0.001
  Gender                                                 
  Male                            1                      
  Female                          0.970   0.897--1.049   0.445
  MA                                                     
  Chemotherapy regimen                                   
  5‐FU                            1                      
  Oxaliplatin                     0.851   0.611--1.185   0.340
  Age at diagnosis, years                                
  \<70                            1                      
  70--74                          1.136   0.890--1.450   0.306
  75--79                          1.243   0.975--1.586   0.079
  80--84                          1.602   1.226--2.094   0.001
  \>84                            1.326   0.865--2.033   0.195
  Year at diagnosis                                      
  1992--1996                      1                      
  1997--2000                      0.867   0.685--1.098   0.236
  2001--2004                      0.939   0.755--1.167   0.570
  2005--2008                      0.707   0.510--0.981   0.038
  HCC risk score                                         
  1st quartile                    1                      
  2nd quartile                    1.114   0.876--1.417   0.378
  3rd quartile                    1.297   1.026--1.639   0.030
  4th quartile                    1.316   1.029--1.683   0.029
  Number of examined lymph node                          
  \<12                            1                      
  ≥12                             0.705   0.596--0.834   \<0.001
  pT category                                            
  T1                              1                      
  T2                              1.066   0.476--2.386   0.876
  T3                              2.038   1.048--3.965   0.036
  T4a                             3.166   1.589--6.308   0.001
  T4b                             4.793   2.358--9.742   \<0.001
  Intestinal obstruction                                 
  No                              1                      
  Yes                             1.258   1.021--1.549   0.031
  Marital status                                         
  Single                          1                      
  Married                         0.846   0.624--1.148   0.284
  Widowed                         0.888   0.645--1.222   0.465
  Others                          1.561   0.951--2.560   0.078
  pN category                                            
  N1a                             1                      
  N1b                             1.286   1.025--1.614   0.030
  N2a                             2.176   1.718--2.756   \<0.001
  N2b                             3.046   2.381--3.897   \<0.001
  Intestinal perforation                                 
  No                              1                      
  Yes                             1.443   0.705--2.955   0.316
  Histological grade                                     
  Well                            1                      
  Moderate                        0.974   0.688--1.378   0.882
  Poor                            1.141   0.794--1.640   0.474
  Undifferentiated                1.250   0.577--2.709   0.572
  Unknown                         0.864   0.555--1.345   0.517

HCC, Hierarchical condition categories; HR, hazard ratio; CI, confidential intervals; MA, mucinous adenocarcinoma; NMA, nonmucinous adenocarcinoma; 5‐FU, 5‐fluorouracil.
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FOLFOX versus CapeOx {#cam41333-sec-0012}
--------------------

We found no difference in survival between the FOLFOX and CapeOx group for NMA (HR: 0.817, 95% CI: 0.190--3.518, *P *=* *0.786) and MA (HR: 0.042, 95% CI: 0.001--92710.202, *P *=* *0.512) in high‐risk stage II patients. Similar results were found for NMA (HR: 1.128, 95% CI: 0.750--1.695, *P *=* *0.562) and MA (HR: 0.746, 95% CI: 0.234--2.382, *P *=* *0.618) in stage III patients. Detailed information is shown in Table [7](#cam41333-tbl-0007){ref-type="table-wrap"}.

###### 

Univariate prognostic analysis between the FOLFOX and CapeOx groups

                              HR      95% CI             *P*
  --------------------------- ------- ------------------ -------
  NMA in low‐risk stage II    0.044   0.001--38913059    0.065
  NMA in high‐risk stage II   0.817   0.190--3.518       0.786
  NMA in stage III            1.128   0.750--1.695       0.562
  MA in low‐risk stage II     --      --                 --
  MA in high‐risk stage II    0.042   0.001--92710.202   0.512
  MA in stage III             0.746   0.234--2.382       0.618

MA, mucinous adenocarcinoma; NMA, nonmucinous adenocarcinoma; HR, hazard ratio; CI, confidential intervals.
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Discussion {#cam41333-sec-0013}
==========

Mucinous adenocarcinoma is a relatively common histological subtype of colon adenocarcinoma, yet the clinical significance of its histological designation remains unclear. The rate of MA was 14.1% in our study and 20--30% in previous studies [20](#cam41333-bib-0020){ref-type="ref"}, [21](#cam41333-bib-0021){ref-type="ref"}. Moreover, other studies reported that MA occurred in 10--20% cases of colon cancer [22](#cam41333-bib-0022){ref-type="ref"}, [23](#cam41333-bib-0023){ref-type="ref"}. The reason may be that the definition of MA has not been consistent across studies [24](#cam41333-bib-0024){ref-type="ref"}. In our study, MA was defined according to the MORPHOLOGY CODE of SEER (ICD‐O‐3: 8480). Most previous studies demonstrated worse survival in MA patients compared with NMA [25](#cam41333-bib-0025){ref-type="ref"}, [26](#cam41333-bib-0026){ref-type="ref"}. However, this is contradicted by other research [22](#cam41333-bib-0022){ref-type="ref"}. MA is more often discovered in the proximal colon [27](#cam41333-bib-0027){ref-type="ref"}, and in females [23](#cam41333-bib-0023){ref-type="ref"}, and it generally has a more advanced stage at presentation [27](#cam41333-bib-0027){ref-type="ref"}. Whether MA should be considered as an independent prognostic factor is still controversial. To the best of our knowledge, there is no difference in treatment prescribed between NMA and MA. At present, the main treatment for locally advanced colon cancer is curative resection plus chemotherapy.

Most of the benefit of postoperative chemotherapy is reported in the patients with stage III disease. The benefit of chemotherapy for stage II disease is very controversial. In our study, there was no significant difference in survival for NMA and MA patients with stage II cancer between the no‐chemo and 5‐FU groups. For patients with stage III, adjuvant chemotherapy after primary surgical treatment is usually recommended [28](#cam41333-bib-0028){ref-type="ref"}. As would be expected, we found a survival benefit for MA and NMA patients with stage III receiving 5‐FU compared to the no‐chemo group.

Oxaliplatin is a platinum analogue that blocks DNA replication and transcription. It has been permitted in the European Union since 1999 and in the United States since 2002 [29](#cam41333-bib-0029){ref-type="ref"}, [30](#cam41333-bib-0030){ref-type="ref"}. FOLFOX had proven to be highly efficient in treatment of gastrointestinal cancer, which had enabled significant progress in clinical oncology in recent years [31](#cam41333-bib-0031){ref-type="ref"}. Studies have found that the 10‐year OS of patients with stage III disease receiving FOLFOX was significantly increased compared with those receiving 5‐FU alone [32](#cam41333-bib-0032){ref-type="ref"}. However, oxaliplatin causes severe side effects which should not be ignored. These include peripheral neuropathy and gastrointestinal side effects. The primary safety concern with oxaliplatin use is peripheral neuropathy, a cumulative dose‐related toxicity which affects 90% of all treated patients [33](#cam41333-bib-0033){ref-type="ref"}. Incidence of grade 3 peripheral sensory neuropathy was 12.4% for patients receiving FOLFOX and only 0.2% for patients receiving 5‐FU. Moreover, Andre et al. [34](#cam41333-bib-0034){ref-type="ref"} found that neuropathy was still present in 15.4% of examined patients at 4 years post‐treatment, suggesting that oxaliplatin‐induced neuropathy may not be completely reversible in some patients.

It is quite important to identify which patients could optimally benefit from oxaliplatin treatment. This study found that patients with locally advanced colon cancer whose histological type is NMA can benefit from oxaliplatin, while those with MA cannot. We compared the prognosis of patients stratified by histological type between the 5‐FU and oxaliplatin groups. We found that in stage III and high‐risk stage II MA, adding oxaliplatin to 5‐FU in the adjuvant setting did not prolong CSS. On the contrary, the oxaliplatin regimen improved CSS in NMA patients compared with the 5‐FU regimen. The results of the PS‐match and Cox proportional hazards models in high‐risk stage II and stage III patients confirmed these findings, as do the results of the interaction analysis in stage III patients. Moreover, there were a relatively small number of patients in subgroup analyses, and therefore, more studies with a larger sample size are necessary.

In spite of this, we still could not clearly define a reason for our findings. However, we elaborated upon this phenomenon to provide some preliminary data for markers identifying the efficiency of oxaliplatin in MA, and it is important to continue researching its specific mechanism in future studies.

Our findings should be interpreted in the context of several limitations. The information on perineural, vascular, and lymphatic invasion was not available in the SEER‐Medicare database. To the best of our best knowledge, no studies to date evaluated the impact of perineural, vascular, and lymphatic invasion on the sensitivity of oxaliplatin, and no definite conclusions could be made because of limited data. Therefore, more studies are necessary to address this problem more conclusively.

The nonavailability of the microsatellite instability (MSI) status in the SEER‐Medicare database was a major limitation. It was reported that 27% of MA patients were in MSI‐H status and only 12% of NMA patients were in the MSI‐H status [35](#cam41333-bib-0035){ref-type="ref"}. In addition, Kim reported the prognosis of MA associated with the MSI‐H status [36](#cam41333-bib-0036){ref-type="ref"}. It is well known that patients with MSI‐H stage II colon cancer do not benefit from 5‐FU therapy in survival [9](#cam41333-bib-0009){ref-type="ref"}. In contrast, whether the MSI status can affect FOLFOX efficacy in stage III patients remains controversial. A previous study found no difference between pMMR and dMMR in survival of patients with stage III colon cancer undergoing FOLFOX adjuvant chemotherapy [37](#cam41333-bib-0037){ref-type="ref"}. In contrast, another study indicated that survival was significantly higher in patients undergoing FOLFOX with dMMR tumors compared to those with pMMR tumors [38](#cam41333-bib-0038){ref-type="ref"}. Whether the MSI status interacted with the influence of MA on the efficacy of FOLFOX needs to be better studied.

In addition, few patients were aged \<65 years at the time of diagnosis in our study (3.2%), which may limit the application of these findings to younger patients with colon cancer. It was reported that the efficacy of oxaliplatin was poor for older adults [8](#cam41333-bib-0008){ref-type="ref"}. Therefore, we took age into account when recruiting the population for the PS‐Match analysis. Moreover, it could be also a major confounding point, in that MSI and mucinous patients seem more frequent in older population. Since that, it is important to continue researching this problem in future studies.

Finally, although both a PS‐matched technique and a Cox proportional hazards model were used to eliminate known relevant confounders, the potential for confounding based on patients selection could not be eliminated completely, as it was a retrospective exploratory study. Further prospective study was needed to verify our findings in future.

In summary, for patients with resected colon cancer who received 5‐FU‐based postoperative chemotherapy, oxaliplatin chemotherapy prolongs CSS for patients with stage III and high‐risk stage II NMA. Conversely, adding oxaliplatin to 5‐FU in postoperative chemotherapy did not improve CSS for patients with stage III or high‐risk stage II MA.
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